RBF Capital’s Contineum Therapeutics CTNM Stock Holding History

RBF Capital’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$328K	Hold	20,000	–	–	0.01%	434
2026 Q1	$261K	Hold	20,000	–	–	0.01%	436
2025 Q4	$229K	Sell	20,000 -20,000	-50%	-$228K	0.01%	503
2025 Q3	$470K	Hold	40,000	–	–	0.02%	412
2025 Q2	$159K	Buy	+40,000	New	+$174K	0.01%	548

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RBF Capital's CTNM Position: Q2 2026 in Review

RBF Capital held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 20,000 shares worth $328K. The position accounts for 0.01% of the portfolio, ranked #434.

RBF Capital first reported a position in CTNM in Q2 2025 and has held it in 5 quarters since. The position peaked at $470K in Q3 2025. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

RBF Capital held 20,000 shares of Contineum Therapeutics worth $328K as of Q2 2026.
RBF Capital left its Contineum Therapeutics share count unchanged in Q2 2026.
Contineum Therapeutics made up 0.01% of RBF Capital's portfolio in Q2 2026, its #434 holding.
RBF Capital first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 5 quarters since.
RBF Capital's Contineum Therapeutics position peaked at $470K in Q3 2025.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.